Related Experiment Video
Updated: Apr 19, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment
Elsje Pienaar1, Nicholas A Cilfone2, Philana Ling Lin3
1Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA; Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, USA.
Computational models reveal antibiotics often fail to reach effective concentrations within tuberculosis granulomas, hindering treatment. Optimizing antibiotic dosing and regimens is crucial for effective tuberculosis therapy.
Area of Science:
- Pharmacology
- Computational Biology
- Infectious Diseases
Background:
- Active tuberculosis (TB) remains a global health challenge due to complex factors hindering elimination.
- Developing optimal TB therapies is complicated by the vast possibilities for antibiotic doses, regimens, and combinations.
- Drug penetration into the lung granuloma, the site of TB infection, is a significant challenge.
Purpose of the Study:
- To integrate computational models of granuloma dynamics with pharmacokinetic and pharmacodynamic models for anti-TB antibiotics.
- To predict antibiotic behavior within granulomas and identify factors influencing treatment outcomes.
- To reduce the need for extensive pre-clinical and clinical trials by refining antibiotic strategies.
Main Methods:
- Integration of a computational model of granuloma formation and function with plasma and lung tissue pharmacokinetic/pharmacodynamic models.
- Calibration of the integrated model using animal data.
- Simulation of antibiotic concentrations and bacterial dynamics within granulomas for two first-line anti-TB drugs.
Main Results:
- Antibiotics frequently fall below effective concentrations within granulomas, allowing bacterial growth between doses.
- Concentration gradients of antibiotics are observed within granulomas, with lower levels in the center.
- Bacterial subpopulations during treatment are primarily intracellular or in non-replicative hypoxic areas.
- Pre-treatment granuloma severity predicts treatment success on an individual granuloma basis.
Conclusions:
- Antibiotic under-dosing within granulomas contributes to the prolonged treatment durations required for TB.
- Understanding granuloma drug penetration and spatial dynamics is essential for designing more effective TB therapies.
- Individual granuloma characteristics are key predictors of treatment response, suggesting personalized therapeutic approaches may be beneficial.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:

